Research & Development

Latest science and publications.

Read up on our research and development activities.

White Paper

May 2026

Precision is the adherence intervention.

Aspirin works. Yet U.S. preeclampsia rates keep rising. The failure is not pharmacological — it is a failure of risk identification that asks 9 in 10 pregnant women to take a drug they will rationally decline. A look at the evidence for why first-trimester multi-modal screening, not broader checklists, will finally close the preeclampsia prevention gap.

Read white paper

Preprint

March 2026

First-Trimester Multi-modal cfDNA Analysis for Prediction of Preterm and Term Preeclampsia

First-trimester multi-modal, tissue-resolved cfDNA analysis enables early risk stratification across the full clinical spectrum of preeclampsia from a single routine blood sample.

Read on medRxiv